# Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Study · id `cardio:ct-nct05934526` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05934526](<https://clinicaltrials.gov/study/NCT05934526>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05934526

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 390 participants.

## Technical summary

Registry record NCT05934526. Randomized; double masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2025-11-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 390 participants (enrolled count; ClinicalTrials.gov record NCT05934526, source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)
- Started: 2023-12-28 (actual) (ClinicalTrials.gov record NCT05934526, source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)
- Primary completion: 2025-11-27 (actual) (ClinicalTrials.gov record NCT05934526, source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)
- Completion: 2025-12-22 (actual) (ClinicalTrials.gov record NCT05934526, source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Colombia; Czechia; Denmark; France; Germany; Greece; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; Serbia; Singapore; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT05934526, source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05934526-2026-05-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): Seralutinib
- Intervention (Device): Generic Dry Powder Inhaler
- Lead sponsor: GB002, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 64c323eccb784e530cd0c8aa09336f28ae18284e865494226726c68eefcbfb08
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
